Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors
OwnerTheodosia Maina-Nock, Berthold Artur Nock +1inventors
InventorsTheodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
Life of this patent
Estimating the term…
Abstract
The present invention relates to a compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound to the disease site.
Claims11
A method of diagnosing cancer the method comprising co-administering a diagnostic radiolabeled biodegradable peptide analog with a neutral endopeptidase (NEP) inhibitor selected from the group consisting of phosphoramidon and racecadotril and imaging and/or detecting the radiolabeled biodegradable peptide analog by generating an image;
- wherein the peptide-portion of the radiolabeled biodegradable peptide analog is a CCK selected from the group consisting of gastrins and minigastrins.
Dependencies are inferred from the claim text.